Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Nov;71(11):8368–8376. doi: 10.1128/jvi.71.11.8368-8376.1997

Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

D Matteucci 1, M Pistello 1, P Mazzetti 1, S Giannecchini 1, D Del Mauro 1, I Lonetti 1, L Zaccaro 1, C Pollera 1, S Specter 1, M Bendinelli 1
PMCID: PMC192298  PMID: 9343192

Abstract

Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.

Full Text

The Full Text of this article is available as a PDF (762.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S., Lohman B., Marthas M., Giavedoni L., el-Amad Z., Haigwood N. L., Scandella C. J., Gardner M. B., Luciw P. A., Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994 Feb;10(2):195–204. doi: 10.1089/aid.1994.10.195. [DOI] [PubMed] [Google Scholar]
  2. Baldinotti F., Matteucci D., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol. 1994 Jul;68(7):4572–4579. doi: 10.1128/jvi.68.7.4572-4579.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bendinelli M., Pistello M., Lombardi S., Poli A., Garzelli C., Matteucci D., Ceccherini-Nelli L., Malvaldi G., Tozzini F. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev. 1995 Jan;8(1):87–112. doi: 10.1128/cmr.8.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bevan M. J., Braciale T. J. Why can't cytotoxic T cells handle HIV? Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5765–5767. doi: 10.1073/pnas.92.13.5765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bishop S. A., Stokes C. R., Gruffydd-Jones T. J., Whiting C. V., Humphries J. E., Osborne R., Papanastasopoulou M., Harbour D. A. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. Vaccine. 1996 Sep;14(13):1243–1250. doi: 10.1016/s0264-410x(96)00023-0. [DOI] [PubMed] [Google Scholar]
  6. Cammarota G., Da Prato L., Nicoletti E., Matteucci D., Bendinelli M., Pistello M. Quantitation of feline immunodeficiency proviruses in doubly infected cats using competitive PCR and a fluorescence-based RFLP. J Virol Methods. 1996 Oct;62(1):21–31. doi: 10.1016/0166-0934(96)02085-x. [DOI] [PubMed] [Google Scholar]
  7. Cammarota G., Matteucci D., Pistello M., Nicoletti E., Giannecchini S., Bendinelli M. Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein. AIDS Res Hum Retroviruses. 1996 Jan 20;12(2):173–175. doi: 10.1089/aid.1996.12.173. [DOI] [PubMed] [Google Scholar]
  8. Chan W. L., Rodgers A., Grief C., Almond N., Ellis S., Flanagan B., Silvera P., Bootman J., Stott J., Kent K. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS. 1995 Mar;9(3):223–228. [PubMed] [Google Scholar]
  9. Diehl L. J., Mathiason-Dubard C. K., O'Neil L. L., Obert L. A., Hoover E. A. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J Virol. 1995 Oct;69(10):6149–6157. doi: 10.1128/jvi.69.10.6149-6157.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Elder J. H., Phillips T. R. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv Virus Res. 1995;45:225–247. doi: 10.1016/s0065-3527(08)60062-7. [DOI] [PubMed] [Google Scholar]
  11. Flynn J. N., Keating P., Hosie M. J., Mackett M., Stephens E. B., Beatty J. A., Neil J. C., Jarrett O. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J Immunol. 1996 Oct 15;157(8):3658–3665. [PubMed] [Google Scholar]
  12. Fultz P. N., Nara P., Barre-Sinoussi F., Chaput A., Greenberg M. L., Muchmore E., Kieny M. P., Girard M. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 1992 Jun 19;256(5064):1687–1690. doi: 10.1126/science.256.5064.1687. [DOI] [PubMed] [Google Scholar]
  13. Giannecchini S., Matteucci D., Mazzetti P., Bendinelli M. Incubation time for feline immunodeficiency virus cultures. J Clin Microbiol. 1996 Aug;34(8):2036–2038. doi: 10.1128/jcm.34.8.2036-2038.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hilleman M. R. Whether and when an AIDS vaccine? Nat Med. 1995 Nov;1(11):1126–1129. doi: 10.1038/nm1195-1126. [DOI] [PubMed] [Google Scholar]
  15. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M., Jr, Elkins W. R., Alvord W. G., Montefiori D. C. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996 Jun;70(6):3741–3752. doi: 10.1128/jvi.70.6.3741-3752.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hosie M. J., Dunsford T. H., de Ronde A., Willett B. J., Cannon C. A., Neil J. C., Jarrett O. Suppression of virus burden by immunization with feline immunodeficiency virus Env protein. Vaccine. 1996 Apr;14(5):405–411. doi: 10.1016/0264-410x(95)00193-5. [DOI] [PubMed] [Google Scholar]
  17. Hosie M. J., Flynn J. N. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J Virol. 1996 Nov;70(11):7561–7568. doi: 10.1128/jvi.70.11.7561-7568.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hosie M. J., Osborne R., Yamamoto J. K., Neil J. C., Jarrett O. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol. 1995 Feb;69(2):1253–1255. doi: 10.1128/jvi.69.2.1253-1255.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Israel Z. R., Edmonson P. F., Maul D. H., O'Neil S. P., Mossman S. P., Thiriart C., Fabry L., Van Opstal O., Bruck C., Bex F. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994 Mar;68(3):1843–1853. doi: 10.1128/jvi.68.3.1843-1853.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jeng C. R., English R. V., Childers T., Tompkins M. B., Tompkins W. A. Evidence for CD8+ antiviral activity in cats infected with feline immunodeficiency virus. J Virol. 1996 Apr;70(4):2474–2480. doi: 10.1128/jvi.70.4.2474-2480.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jordan H. L., Howard J., Tompkins W. A., Kennedy-Stoskopf S. Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus). J Virol. 1995 Nov;69(11):7328–7333. doi: 10.1128/jvi.69.11.7328-7333.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., da Prato L., Bandecchi P., Tozzini F. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 1994 Dec;68(12):8374–8379. doi: 10.1128/jvi.68.12.8374-8379.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Luke W., Coulibaly C., Dittmer U., Voss G., Oesterle R., Makoschey B., Sauermann U., Jurkiewicz E., Stahl-Henning C., Petry H. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Virology. 1996 Feb 15;216(2):444–450. doi: 10.1006/viro.1996.0082. [DOI] [PubMed] [Google Scholar]
  24. Lutz H., Hofmann-Lehmann R., Bauer-Pham K., Holznagel E., Tozzini F., Bendinelli M., Reubel G., Aubert A., Davis D., Cox D. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection. Vet Immunol Immunopathol. 1995 May;46(1-2):103–113. doi: 10.1016/0165-2427(94)07010-5. [DOI] [PubMed] [Google Scholar]
  25. Mathieson B. J. CTL to HIV-1: surrogates or sirens. Nat Med. 1995 Apr;1(4):304–305. doi: 10.1038/nm0495-304. [DOI] [PubMed] [Google Scholar]
  26. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Del Mauro D., Zaccaro L., Bandecchi P., Tozzini F., Bendinelli M. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol. 1996 Jan;70(1):617–622. doi: 10.1128/jvi.70.1.617-622.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mossman S. P., Bex F., Berglund P., Arthos J., O'Neil S. P., Riley D., Maul D. H., Bruck C., Momin P., Burny A. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol. 1996 Mar;70(3):1953–1960. doi: 10.1128/jvi.70.3.1953-1960.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. O'Brien W. A., Grovit-Ferbas K., Namazi A., Ovcak-Derzic S., Wang H. J., Park J., Yeramian C., Mao S. H., Zack J. A. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995 Aug 1;86(3):1082–1089. [PubMed] [Google Scholar]
  29. Pistello M., Cammarota G., Nicoletti E., Matteucci D., Curcio M., Del Mauro D., Bendinelli M. Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B. J Gen Virol. 1997 Sep;78(Pt 9):2247–2257. doi: 10.1099/0022-1317-78-9-2247. [DOI] [PubMed] [Google Scholar]
  30. Pistello M., Menzo S., Giorgi M., Da Prato L., Cammarota G., Clementi M., Bendinelli M. Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. Mol Cell Probes. 1994 Jun;8(3):229–234. doi: 10.1006/mcpr.1994.1032. [DOI] [PubMed] [Google Scholar]
  31. Poignard P., Klasse P. J., Sattentau Q. J. Antibody neutralization of HIV-1. Immunol Today. 1996 May;17(5):239–246. doi: 10.1016/0167-5699(96)10007-4. [DOI] [PubMed] [Google Scholar]
  32. Richardson J., Fossati I., Moraillon A., Castelot S., Sonigo P., Pancino G. Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope. J Gen Virol. 1996 Apr;77(Pt 4):759–771. doi: 10.1099/0022-1317-77-4-759. [DOI] [PubMed] [Google Scholar]
  33. Rigby M. A., Mackay N., Reid G., Osborne R., Neil J. C., Jarrett O. Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein. Vaccine. 1996 Aug;14(12):1095–1102. doi: 10.1016/0264-410x(96)00060-6. [DOI] [PubMed] [Google Scholar]
  34. Sabin A. B. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8852–8855. doi: 10.1073/pnas.89.18.8852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Siebelink K. H., Tijhaar E., Huisman R. C., Huisman W., de Ronde A., Darby I. H., Francis M. J., Rimmelzwaan G. F., Osterhaus A. D. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol. 1995 Jun;69(6):3704–3711. doi: 10.1128/jvi.69.6.3704-3711.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stanley S. K., Ostrowski M. A., Justement J. S., Gantt K., Hedayati S., Mannix M., Roche K., Schwartzentruber D. J., Fox C. H., Fauci A. S. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996 May 9;334(19):1222–1230. doi: 10.1056/NEJM199605093341903. [DOI] [PubMed] [Google Scholar]
  37. Staprans S. I., Hamilton B. L., Follansbee S. E., Elbeik T., Barbosa P., Grant R. M., Feinberg M. B. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995 Dec 1;182(6):1727–1737. doi: 10.1084/jem.182.6.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stott E. J. Anti-cell antibody in macaques. Nature. 1991 Oct 3;353(6343):393–393. doi: 10.1038/353393a0. [DOI] [PubMed] [Google Scholar]
  39. Tozzini F., Matteucci D., Bandecchi P., Baldinotti F., Siebelink K., Osterhaus A., Bendinelli M. Neutralizing antibodies in cats infected with feline immunodeficiency virus. J Clin Microbiol. 1993 Jun;31(6):1626–1629. doi: 10.1128/jcm.31.6.1626-1629.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Verschoor E. J., Willemse M. J., Stam J. G., van Vliet A. L., Pouwels H., Chalmers S. K., Horzinek M. C., Sondermeijer P. J., Hesselink W., de Ronde A. Evaluation of subunit vaccines against feline immunodeficiency virus infection. Vaccine. 1996 Mar;14(4):285–289. doi: 10.1016/0264-410x(95)00205-f. [DOI] [PubMed] [Google Scholar]
  41. Wyand M. S., Manson K. H., Garcia-Moll M., Montefiori D., Desrosiers R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol. 1996 Jun;70(6):3724–3733. doi: 10.1128/jvi.70.6.3724-3733.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yamamoto J. K., Hansen H., Ho E. W., Morishita T. Y., Okuda T., Sawa T. R., Nakamura R. M., Pedersen N. C. Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc. 1989 Jan 15;194(2):213–220. [PubMed] [Google Scholar]
  43. Yamamoto J. K., Hohdatsu T., Olmsted R. A., Pu R., Louie H., Zochlinski H. A., Acevedo V., Johnson H. M., Soulds G. A., Gardner M. B. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol. 1993 Jan;67(1):601–605. doi: 10.1128/jvi.67.1.601-605.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES